Methods for determining a patient's susceptibility of contracting a nosocomial infection and for establishing a prognosis of the progression of septic syndrome

Patent metadata

Field	Value
Publication number	US-11299768-B2
Application number	US-201013140678-A
Country	US
Kind code	B2
Filing date	Jan 18, 2010
Priority date	Jan 19, 2009
Publication date	Apr 12, 2022
Grant date	Apr 12, 2022

Abstract

A method for determining a patient's susceptibility of contracting a nosocomial infection that includes obtaining a biological sample from the patient and extracting biological material from the biological sample; preparing a specific reagent of an expression product of at least one target gene selected from S100A9 and S100A8 target genes; and determining the expression of at least one of the target genes S100A9 and S100A8, where overexpression relative to a specified threshold value indicates susceptibility of contracting a nosocomial infection.

First claim

The invention claimed is:

1. A method comprising:
a) obtaining blood samples from a human patient with septic shock at multiple time points after septic shock onset, at least one of the time points being between 7 and 10 days after septic shock onset;
b) extracting nucleic acids from the blood samples; and
c) measuring an overexpression of the S100A9 gene relative to a predetermined threshold value in at least the blood sample(s) obtained between 7 and 10 days after septic shock onset,
wherein the overexpression is measured via an amplification method comprising the use of a first primer consisting of SEQ ID NO: 1 and a second primer consisting of SEQ ID NO: 2.

2. The method as claimed in claim 1 , wherein RNA is the nucleic acid extracted from the blood samples, and cDNA is generated from the RNA by an amplification method.

3. The method as claimed in claim 1 , wherein the amplification method is a real-time PCR amplification method.

4. The method according to claim 1 , wherein septic shock is characterized by an identified infectious site and persistent hypotension.

5. A method comprising:
a) obtaining blood samples from a human patient with septic shock at multiple time points after septic shock onset, at least one of the time points being between 7 and 10 days after septic shock onset;
b) extracting nucleic acids from the blood samples; and
c) measuring an overexpression of the S100A8 gene relative to a predetermined threshold value in at least the blood sample(s) obtained between 7 and 10 days after septic shock onset, the threshold value being indicative of either a healthy subject or a non-surviving septic shock patient,
wherein the overexpression is measured via an amplification method comprising the use of a first primer consisting of SEQ ID NO: 3 and a second primer consisting of SEQ ID NO: 4.

6. The method as claimed in claim 5 , wherein RNA is the nucleic acid extracted from the blood samples, and cDNA is generated from the RNA by an amplification method.

7. The method as claimed in claim 5 , wherein the amplification method is a real-time PCR amplification method.

8. The method according to claim 5 , wherein septic shock is characterized by an identified infectious site and persistent hypotension.

Assignees

• Cazalis Marie Angelique
• Lepape Alain
• Monneret Guillaume
• Mougin Bruno
• Pachot Alexandre
• Biomerieux Sa
• Hospices Civils Lyon

Inventors

• Cazalis Marie-Angelique
• Lepape Alain
• Monneret Guillaume
• Mougin Bruno
• Pachot Alexandre

Classifications

• C12Q1/6809 Primary

  Methods for determination or identification of nucleic acids involving differential detection · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title

• G01N33/15

  Medicinal preparations {; Physical properties thereof, e.g. dissolubility} · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q1/686

  Polymerase chain reaction [PCR] · CPC title